Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.
Convection Enhanced Delivery (CED)
IL4R
MDNA55
immunotherapy
recurrent glioblastoma
treatment outcome
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
02 06 2023
02 06 2023
Historique:
medline:
5
6
2023
pubmed:
15
1
2023
entrez:
14
1
2023
Statut:
ppublish
Résumé
MDNA55 is an interleukin 4 receptor (IL4R)-targeting toxin in development for recurrent GBM, a universally fatal disease. IL4R is overexpressed in GBM as well as cells of the tumor microenvironment. High expression of IL4R is associated with poor clinical outcomes. MDNA55-05 is an open-label, single-arm phase IIb study of MDNA55 in recurrent GBM (rGBM) patients with an aggressive form of GBM (de novo GBM, IDH wild-type, and nonresectable at recurrence) on their 1st or 2nd recurrence. MDNA55 was administered intratumorally as a single dose treatment (dose range of 18 to 240 ug) using convection-enhanced delivery (CED) with up to 4 stereo-tactically placed catheters. It was co-infused with a contrast agent (Gd-DTPA, Magnevist®) to assess distribution in and around the tumor margins. The flow rate of each catheter did not exceed 10μL/min to ensure that the infusion duration did not exceed 48 h. The primary endpoint was mOS, with secondary endpoints determining the effects of IL4R status on mOS and PFS. MDNA55 showed an acceptable safety profile at doses up to 240 μg. In all evaluable patients (n = 44) mOS was 11.64 months (80% one-sided CI 8.62, 15.02) and OS-12 was 46%. A subgroup (n = 32) consisting of IL4R High and IL4R Low patients treated with high-dose MDNA55 (>180 ug) showed the best benefit with mOS of 15 months, OS-12 of 55%. Based on mRANO criteria, tumor control was observed in 81% (26/32), including those patients who exhibited pseudo-progression (15/26). MDNA55 demonstrated tumor control and promising survival and may benefit rGBM patients when treated at high-dose irrespective of IL4R expression level.Trial Registration: Clinicaltrials.gov NCT02858895.
Sections du résumé
BACKGROUND
MDNA55 is an interleukin 4 receptor (IL4R)-targeting toxin in development for recurrent GBM, a universally fatal disease. IL4R is overexpressed in GBM as well as cells of the tumor microenvironment. High expression of IL4R is associated with poor clinical outcomes.
METHODS
MDNA55-05 is an open-label, single-arm phase IIb study of MDNA55 in recurrent GBM (rGBM) patients with an aggressive form of GBM (de novo GBM, IDH wild-type, and nonresectable at recurrence) on their 1st or 2nd recurrence. MDNA55 was administered intratumorally as a single dose treatment (dose range of 18 to 240 ug) using convection-enhanced delivery (CED) with up to 4 stereo-tactically placed catheters. It was co-infused with a contrast agent (Gd-DTPA, Magnevist®) to assess distribution in and around the tumor margins. The flow rate of each catheter did not exceed 10μL/min to ensure that the infusion duration did not exceed 48 h. The primary endpoint was mOS, with secondary endpoints determining the effects of IL4R status on mOS and PFS.
RESULTS
MDNA55 showed an acceptable safety profile at doses up to 240 μg. In all evaluable patients (n = 44) mOS was 11.64 months (80% one-sided CI 8.62, 15.02) and OS-12 was 46%. A subgroup (n = 32) consisting of IL4R High and IL4R Low patients treated with high-dose MDNA55 (>180 ug) showed the best benefit with mOS of 15 months, OS-12 of 55%. Based on mRANO criteria, tumor control was observed in 81% (26/32), including those patients who exhibited pseudo-progression (15/26).
CONCLUSIONS
MDNA55 demonstrated tumor control and promising survival and may benefit rGBM patients when treated at high-dose irrespective of IL4R expression level.Trial Registration: Clinicaltrials.gov NCT02858895.
Identifiants
pubmed: 36640127
pii: 6987580
doi: 10.1093/neuonc/noac285
pmc: PMC10237418
doi:
Substances chimiques
Receptors, Interleukin-4
0
Banques de données
ClinicalTrials.gov
['NCT02858895']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1085-1097Subventions
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227136
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS079697
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS123808
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Références
Toxins (Basel). 2010 Nov;2(11):2519-83
pubmed: 22069564
J Neuroimmunol. 1992 Sep;40(1):81-7
pubmed: 1517399
Mol Ther. 2017 Jan 4;25(1):232-248
pubmed: 28129117
Neurotherapeutics. 2017 Apr;14(2):358-371
pubmed: 28299724
Acta Neurochir (Wien). 2007 Mar;149(3):245-52; discussion 252-3
pubmed: 17273889
Eur J Cancer. 2012 Sep;48(14):2192-202
pubmed: 22608262
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
J Clin Oncol. 2009 Feb 10;27(5):740-5
pubmed: 19114704
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Cancer. 2005 May 15;103(10):2132-42
pubmed: 15830341
J Biol Chem. 1997 Dec 12;272(50):31707-11
pubmed: 9395513
Zentralbl Neurochir. 2002;63(1):23-8
pubmed: 12098080
J Neurooncol. 2017 Sep;134(3):495-504
pubmed: 28382534
J Neurooncol. 2017 Oct;135(1):183-192
pubmed: 28730289
Clin Cancer Res. 2016 Mar 1;22(5):1055-8
pubmed: 26463707
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
Neurotherapeutics. 2008 Jan;5(1):123-7
pubmed: 18164491
Oncologist. 2009 Nov;14(11):1131-8
pubmed: 19897538
Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S59-67
pubmed: 25722934
Lancet Oncol. 2021 Oct;22(10):e456-e465
pubmed: 34592195
Cancer Res. 2001 Nov 15;61(22):8058-61
pubmed: 11719427
Nat Rev Neurol. 2014 Jul;10(7):372-85
pubmed: 24912512
J Neurooncol. 2004 Jan;66(1-2):197-201
pubmed: 15015787
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Cancer Res. 2013 Nov 1;73(21):6413-23
pubmed: 24030977
World Neurosurg. 2019 Sep;129:90-100
pubmed: 31152883
J Neurooncol. 2003 Aug-Sep;64(1-2):125-37
pubmed: 12952293
Clin Cancer Res. 2002 Jan;8(1):258-66
pubmed: 11801567
J Mol Biol. 2001 Dec 7;314(4):823-37
pubmed: 11734000
J Neurosurg. 2017 Jan;126(1):191-200
pubmed: 27035164
Cancers (Basel). 2019 Feb 26;11(3):
pubmed: 30813636
Cancer Res. 2007 Oct 15;67(20):9903-12
pubmed: 17942922
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Neuro Oncol. 2013 Jan;15(1):4-27
pubmed: 23136223
Ann Oncol. 2001 Feb;12(2):259-66
pubmed: 11300335
J Neurooncol. 2018 Feb;136(3):463-474
pubmed: 29168083
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6889-93
pubmed: 8041715
Clin Cancer Res. 2021 Jul 15;27(14):3916-3925
pubmed: 33863808
Neuroimage. 2011 Jan;54 Suppl 1:S196-203
pubmed: 19761848
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
ESMO Open. 2019 Jun 17;4(Suppl 2):e000520
pubmed: 31297242